K

Knotus Co Ltd
KOSDAQ:278650

Watchlist Manager
Knotus Co Ltd
KOSDAQ:278650
Watchlist
Price: 2 160 KRW Market Closed
Market Cap: 181.9B KRW
Have any thoughts about
Knotus Co Ltd?
Write Note

Knotus Co Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Knotus Co Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
K
Knotus Co Ltd
KOSDAQ:278650
Cash & Cash Equivalents
â‚©68.8B
CAGR 3-Years
105%
CAGR 5-Years
83%
CAGR 10-Years
N/A
Samsung Biologics Co Ltd
KRX:207940
Cash & Cash Equivalents
â‚©973.5B
CAGR 3-Years
129%
CAGR 5-Years
147%
CAGR 10-Years
N/A
S
ST Pharm Co Ltd
KOSDAQ:237690
Cash & Cash Equivalents
â‚©50.1B
CAGR 3-Years
6%
CAGR 5-Years
33%
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Cash & Cash Equivalents
â‚©5.4B
CAGR 3-Years
20%
CAGR 5-Years
33%
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Cash & Cash Equivalents
â‚©15.5B
CAGR 3-Years
5%
CAGR 5-Years
14%
CAGR 10-Years
61%
C
Cellivery Therapeutics Inc
KOSDAQ:268600
Cash & Cash Equivalents
â‚©589.8m
CAGR 3-Years
-72%
CAGR 5-Years
-38%
CAGR 10-Years
N/A
No Stocks Found

Knotus Co Ltd
Glance View

Market Cap
181.9B KRW
Industry
Life Sciences Tools & Services

KNOTUS Co. Ltd. engages in the provision of clinical research services. The company is headquartered in Incheon, Incheon. The company went IPO on 2019-11-27. is a Korea-based company principally engaged in the nonclinical experiment business. Along with subsidiaries, the Company operates its business through three segments. The Nonclinical Contract Research Organization (CRO) Business segment conducts nonclinical experiments on new developed substances such as new drugs, and tests the efficacy and pharmacodynamics of the substances. This segment also provides services including new drug development related equipment, software and analysis of experimental results. The Animal Laboratory Construction Business segment is engaged in the construction and design of animal laboratories and the supply of reagent consumables. The Pet Business segment is engaged in the development of animal medicines and the sale of pet supplies.

Intrinsic Value
2 258.02 KRW
Undervaluation 4%
Intrinsic Value
Price
K

See Also

What is Knotus Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
68.8B KRW

Based on the financial report for Dec 31, 2023, Knotus Co Ltd's Cash & Cash Equivalents amounts to 68.8B KRW.

What is Knotus Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
83%

Over the last year, the Cash & Cash Equivalents growth was 363%. The average annual Cash & Cash Equivalents growth rates for Knotus Co Ltd have been 105% over the past three years , 83% over the past five years .

Back to Top